Q2 2021 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Second Quarter 2021 Conference Call. (Operator Instructions). I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks, everyone, for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and development, will provide an update on omecamtiv mecarbil, including the secondary analyses from GALACTIC-HF, our positive Phase III clinical trial of omecamtiv mecarbil as well as recent interactions and next steps with the FDA.
Next, Andrew Callos, our EVP and Chief Commercial Officer, will provide an update on progress towards our go-to-market strategy for omecamtiv mecarbil and how those plans intersect with our franchise development strategies and our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |